Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

Autor: Bidard FC; Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.; INSERM Center of Clinical Investigations in Biotherapies of Cancer (CIC-BT) 1428, Paris, France., Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Kiavue N; Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France., Dureau S; Biometry Unit, Institut Curie, PSL Research University, Paris, France., Kadi A; Biometry Unit, Institut Curie, PSL Research University, Paris, France., Brain E; Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France., Bachelot T; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Bourgeois H; Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Aix-Marseille University, Marseille, France., Ladoire S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France., Naman H; Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins, France., Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France., Gligorov J; Department of Medical Oncology, Hôpital Tenon, Sorbonne Université, Paris, France., Espié M; Department of Medical Oncology, Hôpital Saint-Louis, Paris, France., Emile G; Department of Medical Oncology, Centre François Baclesse, Caen, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Loirat D; Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France., Frank S; Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France., Cabel L; Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France., Diéras V; Formerly with Department of Medical Oncology, Institut Curie, Paris, France.; Now with Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Cayrefourcq L; Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France., Simondi C; Clinical Research Department, Institut Curie, PSL Research University, Paris, France., Berger F; Biometry Unit, Institut Curie, PSL Research University, Paris, France., Alix-Panabières C; Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France., Pierga JY; Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.

Publikováno v: JAMA oncology [JAMA Oncol] 2021 Jan 01; Vol. 7 (1), pp. 34-41.